The NM_000212.3:c.2356C>T variant in ITGB3 predicts the missense change, Arg786Trp. It is absent from gnomAD v2.1.1 and v3 (PM2_supporting). The variant is reported in a compound heterozygous GT patient who has a GOF variant in trans with this variant (PMID: 29439184). The patient meets GT bleeding and laboratory phenotype criteria (PP4_moderate): Platelet aggregation was impaired in response to ADP and TRAP-6, but normal to ristocetin, with low-normal response to collagen (64 U; nv = 56-144). αIIbβ3 surface expression was reduced (CD41/CD42b 0.1 [nv = 0.43+-0.11], expression corrected for platelet volume), and PAC-1 binding induced by platelet stimulation impaired (33.6% with ADP [nv = 74.4+-22.3], 20.3% with TRAP-6 [nv = 80.1+-20.05]). Due to the gain of function variant the patient also shows the macrothrombocytopenia phenotype. The REVEL score (0.334) for this variant is low and does not meet PP3 (>0.7) or BP4 (>0.25) criteria. Functional evidence from transfection studies in CHO cells show that the variant does not affect αIIbβ3 expression or PAC-1 binding, but results in reduced CHO cell spreading (PMID: 29439184), not meeting criteria for PS3. In summary, this variant meets the criteria to be classified as uncertain significance for autosomal recessive Glanzmann Thrombasthenia based on the ACMG/AMP criteria applied, as specified by the ClinGen PD VCEP: PM2_Supporting, PP4_moderate (PD VCEP specifications version 2.1).